Paratek Pharmaceuticals (United States)

Recent papers from Paratek Pharmaceuticals (United States)

1. Activity of omadacycline and comparator agents against rapidly growing mycobacteria by broth microdilution and whole genome sequencingMicrobiology Spectrum · 2026
2. Exhalation delivery system with fluticasone in chronic rhinosinusitis by eosinophil count and asthma and allergy statusAnnals of Allergy Asthma & Immunology · 2026
3. Efficacy of drug regimens containing omadacycline in a murine model of Mycobacterium avium chronic lung infectionFrontiers in Microbiology · 2026
4. Omadacycline Monotherapy in Nontuberculous Mycobacterial Pulmonary Disease Caused by Mycobacterium abscessus : Results From a Phase 2, Double-blind, Randomized, Placebo-controlled StudyClinical Infectious Diseases · 2026
5. P-1535. Omadacycline was Shown to Preserve the Microbiome in a Murine Model of Post-Influenza MRSA PneumoniaOpen Forum Infectious Diseases · 2026
6. P-618. Pooled Microbiological Outcomes from the Phase 3, Randomized OPTIC and OPTIC-2 Trials of Omadacycline vs Moxifloxacin in Community-acquired Bacterial PneumoniaOpen Forum Infectious Diseases · 2026
7. P-1182. In Vitro Activity of Omadacycline and Comparator Agents Against Periodontal PathogensOpen Forum Infectious Diseases · 2026
8. Microbiological Outcomes of Oral Omadacycline Treatment in Adults with Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) Caused by Mycobacterium abscessus complex (MABc): Results from a Phase 2, Double-blind, Randomized, Placebo-controlled, Multi-center TrialOpen Forum Infectious Diseases · 2026
9. Omadacycline versus moxifloxacin for community-acquired bacterial pneumonia (OPTIC-2): a phase 3b, randomised, double-blind, multicentre, controlled, noninferiority trialEClinicalMedicine · 2025
10. Omadacycline as a drug candidate for Mycobacterium avium infections: in vitro insights on single and combination therapiesJournal of Antimicrobial Chemotherapy · 2025
11. Preclinical in vitro and in vivo evaluation of omadacycline against multidrug-resistant Acinetobacter baumanniiAntimicrobial Agents and Chemotherapy · 2025
12. Omadacycline exhibits anti-inflammatory properties and improves survival in a murine model of post-influenza MRSA pneumoniaAntimicrobial Agents and Chemotherapy · 2025
13. Re-evaluation of penicillin and ceftriaxone MIC results to predict susceptibility to the oral cephalosporin, cefpodoxime, in Streptococcus pneumoniae clinical isolates from the United States according to CLSI guidelines (2019–2021)Journal of Clinical Microbiology · 2025
14. In vitro activity and in vivo efficacy of omadacycline against Plasmodium speciesMalaria Journal · 2025
15. In vitro activity of omadacycline against bacterial isolates from bone/joint infections and rare pathogens in the SENTRY antimicrobial surveillance program (2015–2023)Journal of Global Antimicrobial Resistance · 2025
16. Surveillance of omadacycline against 35,000 bacterial clinical isolates from the United States (2019-2023)Diagnostic Microbiology and Infectious Disease · 2025
17. In vitro activity of omadacycline against geographically diverse rapidly growing nontuberculous mycobacteria (NTM) clinical isolatesDiagnostic Microbiology and Infectious Disease · 2024
18. Intravenous Versus Oral Omadacycline or Linezolid for Acute Bacterial Skin and Skin Infections: A post hoc Analysis of the OASIS TrialsInfectious Diseases and Therapy · 2024
19. Omadacycline is active in vitro and in vivo against ciprofloxacin-resistant Bacillus anthracisAntimicrobial Agents and Chemotherapy · 2024
20. Assessment of pharmacokinetics-pharmacodynamics to support omadacycline dosing regimens for the treatment of patients with acute bacterial skin and skin structure infectionsAntimicrobial Agents and Chemotherapy · 2024